Drugs News and Research

RSS

CDC confirms 11 malaria cases in people who traveled to Haiti

The CDC on Thursday said it confirmed that 11 cases of Plasmodium falciparum malaria "among emergency personnel and Haitian residents who traveled to the U.S.," the Miami Herald reports. "The cases include: seven emergency responders, including six military personnel; three Haitian residents who traveled to the U.S., including one Haitian adoptee; and one U.S. traveler," the newspaper writes (Tasker, 3/5).

6 Mar 2010

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Proton pump inhibitors (PPIs) are the most effective agents for treating acid related gastrointestinal (GI) disorders. The utilization of intravenous (IV) formulations of PPIs has dramatically increased in health care institutions for inappropriate indications, route of administration and length of treatment. This is associated with an increased cost burden, increased risk of IV related infections, and utilization of hospital resources.

6 Mar 2010

Inpatient integrative medicine program can have significant impact on pain: Study

Non-traditional therapies relieve pain among a wide range of hospitalized patients as much as 50 percent, according to a first-of-a-kind study in the Journal of Patient Safety.

6 Mar 2010

Recent releases in Global Health

The WHO's March Bulletin is a special themed issue focusing on communicable diseases in Southeast Asia. The publication addresses tuberculosis, cholera, neglected tropical diseases and family planning in the region (March 2010).

6 Mar 2010

Ban, Clinton launch voluntary travel donation for global health

Former President Bill Clinton and U.N. Secretary-General Ban Ki-moon in New York on Thursday launched MASSIVEGOOD - an initiative that allows travelers to make a $2 donation "to fight deadly diseases whenever they buy a plane ticket, book a hotel room or rent a car," Bloomberg/BusinessWeek reports (Varner, 3/4).

6 Mar 2010

Hypertension: Regular nifedipine administration may lead to development of GERD

Nifedipine, a calcium-channel blocker, was shown to decrease lower esophageal sphincter pressure and increase esophageal acid exposure time, while atenolol, a b1 blocker, was shown to inhibit relaxation of the smooth muscle of the esophagus. However, the influence of these anti-hypertensive drugs on the segment of esophageal body contraction using high-resolution manometry was not fully investigated.

5 Mar 2010

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

In an announcement today, Humanetics Corporation reported that its BIO 300 medical radiation countermeasure drug candidate has been issued a U.S. patent. The patent is assigned to the United States of America with Humanetics as the designated licensee.

5 Mar 2010

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Saladax Biomedical, Inc. announced today the close of an $8.4 million Series C Preferred offering led by Excel Venture Management of Boston. Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors. The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

5 Mar 2010

LEO Pharma gains access to Intomics’ biological data analysis expertises

Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics’ unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma’s early drug discovery.

5 Mar 2010

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.

5 Mar 2010

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).

5 Mar 2010

MASSIVEGOOD launched to enable travelers make contributions towards major global health causes

UN Secretary-General Ban Ki-moon and President Bill Clinton join today with international recording artists will.i.am and David Guetta, South African singer Yvonne Chaka Chaka, and director Spike Lee, to launch MASSIVEGOOD, an innovative fundraising movement that will enable travelers to make a "micro-contribution" towards major global health causes every time they buy a plane ticket, reserve a hotel room or rent a car.

5 Mar 2010

China Pharma Holdings reports 21% increase in 2009 revenue

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced financial results for the fiscal year ended December 31, 2009.

5 Mar 2010

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Life Technologies Corporation today announced that it is collaborating with the Translational Genomics Research Institute and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.

5 Mar 2010

Combating liver fluke: Queen's University Belfast heads international research effort

Queen's University Belfast is spearheading a £1 million international research effort to combat liver fluke - a parasite which causes disease in livestock, resulting in billions of pounds in losses every year to farmers around the world.

5 Mar 2010

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

The rapidly growing field of nanotechnology and its future use in cosmetic products holds both enormous potential and potential concern for consumers. Currently, major cosmetic manufacturers have imposed a voluntary ban on the use of nanoparticles in products while they await a ruling from the Food and Drug Administration regarding the safety of this technology.

5 Mar 2010

Forteo to remain Decision Resources' proprietary clinical gold standard for treatment of osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug's effect on reduction of new hip fractures is the attribute that most influences U.S. and European surveyed primary care physicians' (PCPs') prescribing decisions in osteoporosis.

5 Mar 2010

UnitedHealth Group statement: Expand access to quality care for all Americans

We sought to make clear our longstanding commitment to expanding access to quality care for all Americans, and also to discuss the many factors that are driving up the cost of care for millions of people across the United States. To achieve true and sustainable reform, it is essential to first bring costs under control.

5 Mar 2010

Humacyte, Xcellerex collaborate to develop novel vascular graft for transplantation technologies

Humacyte, Inc. and Xcellerex, Inc. have entered into an initial strategic collaboration for Xcellerex to develop a novel manufacturing process that will enable the production of Humacyte’s lead regenerative medicine product using Xcellerex’s XDR single use bioreactor system in its FlexFactory®. Humacyte’s product is a large diameter vascular graft that is based on its innovative and proprietary platform technology for engineering human, extracellular matrix-based tissues that have properties that are similar to native tissues.

5 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

Drugs News and Research

CDC confirms 11 malaria cases in people who traveled to Haiti

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Inpatient integrative medicine program can have significant impact on pain: Study

Recent releases in Global Health

Ban, Clinton launch voluntary travel donation for global health

Hypertension: Regular nifedipine administration may lead to development of GERD

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

LEO Pharma gains access to Intomics’ biological data analysis expertises

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

MASSIVEGOOD launched to enable travelers make contributions towards major global health causes

China Pharma Holdings reports 21% increase in 2009 revenue

Life Technologies, TGen, US Oncology collaborate to sequence genomes of triple negative breast cancer patients

Combating liver fluke: Queen's University Belfast heads international research effort

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

Forteo to remain Decision Resources' proprietary clinical gold standard for treatment of osteoporosis

UnitedHealth Group statement: Expand access to quality care for all Americans

Humacyte, Xcellerex collaborate to develop novel vascular graft for transplantation technologies

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News